In the US pharmaceutical industry, there were 23 private equity deals announced in Q3 2023, worth a total value of $4.1bn, according to GlobalData’s Deals Database. The $1.7bn acquisition of NextGen Healthcare by Thoma Bravo in a going private transaction was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in the US decreased by 67% in Q3 2023 compared with the previous quarter’s total of $12.4bn and rose by 52% as compared to Q3 2022. Related deal volume decreased by 48% in Q3 2023 versus the previous quarter and was 54% lower than in Q3 2022.
The top-ranked financial advisors supporting these private equity deals in the US in Q3 2023 were Cantor Fitzgerald; Houlihan Lokey; Moelis & Co with 5, 5, 4 deals respectively.
The top-ranked legal advisorss supporting these private equity deals in the US Q3 2023 were Kirkland & Ellis; Goodwin Procter; Ropes & Gray with 11, 8, 5 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.